文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

巴瑞替尼联合瑞德西韦治疗住院成人Covid-19

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
PubMed 文献 · N Engl J Med · 2020-12-11
一句话结论住院Covid-19成人中,巴瑞替尼联合瑞德西韦较单用瑞德西韦缩短恢复时间,尤其高流量氧疗或无创通气者获益更明显。

该双盲随机安慰剂对照试验纳入1033例住院Covid-19成人,所有患者接受瑞德西韦≤10天,随机加用巴瑞替尼≤14天或安慰剂。联合组中位恢复时间7天 vs 对照8天(率比1.16,95%CI 1.01-1.32,P=0.03),第15天临床状态改善的比值比1.3(95%CI 1.0-1.6)。入组时接受高流量氧疗或无创通气者恢复时间10天 vs 18天(率比1.51,95%CI 1.10-2.08)。联合组严重不良事件和新发感染更少。

要点

  • 住院Covid-19成人接受巴瑞替尼(≤14天)联合瑞德西韦(≤10天)较单用瑞德西韦缩短恢复时间:7天 vs 8天(率比1.16,95%CI 1.01-1.32,P=0.03)。
  • 入组时接受高流量氧疗或无创通气者获益更明显:联合组恢复时间10天 vs 对照18天(率比1.51,95%CI 1.10-2.08)。
  • 第15天临床状态改善的比值比1.3(95%CI 1.0-1.6)。
  • 28天死亡率联合组5.1% vs 对照组7.8%(HR 0.65,95%CI 0.39-1.09)。
  • 严重不良事件联合组16.0% vs 对照21.0%(差值-5.0个百分点,95%CI -9.8至-0.3,P=0.03),新发感染5.9% vs 11.2%(差值-5.3个百分点,95%CI -8.7至-1.9,P=0.003)。

适用人群与场景

  • 住院成人Covid-19患者;所有患者接受瑞德西韦≤10天,随机加用巴瑞替尼≤14天或安慰剂。
  • 原文未提及具体纳入/排除标准、急诊/ICU/院前场景及病情阶段。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 所有患者接受瑞德西韦≤10天,随机加用巴瑞替尼≤14天或安慰剂(对照)。
  • 原文未提及巴瑞替尼的具体剂量、给药途径、频次及目标值。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 双盲、随机、安慰剂对照试验,共1033例住院Covid-19成人随机(巴瑞替尼联合组515例,对照组518例)。
  • 主要终点恢复时间:联合组中位7天(95%CI 6-8) vs 对照8天(95%CI 7-9),率比1.16(95%CI 1.01-1.32,P=0.03)。
  • 关键次要终点第15天临床状态改善:比值比1.3(95%CI 1.0-1.6)。
  • 入组时接受高流量氧疗或无创通气者恢复时间:联合组10天 vs 对照18天(率比1.51,95%CI 1.10-2.08)。
  • 28天死亡率:联合组5.1% vs 对照7.8%(HR 0.65,95%CI 0.39-1.09)。
  • 严重不良事件:联合组16.0% vs 对照21.0%(差值-5.0个百分点,95%CI -9.8至-0.3,P=0.03);新发感染:5.9% vs 11.2%(差值-5.3个百分点,95%CI -8.7至-1.9,P=0.003)。

证据类型、等级与局限

  • 证据类型:双盲、随机、安慰剂对照试验(RCT)。
  • 局限:原文未明确描述;设计本身为多中心RCT(由美国国家过敏和传染病研究所资助),样本量1033例。

对床旁实践的改变

  • 对住院Covid-19成人,在瑞德西韦治疗基础上加用巴瑞替尼可缩短恢复时间并提高第15天临床状态改善几率,尤其适用于入组时接受高流量氧疗或无创通气者。
  • 联合组严重不良事件和新发感染更少,支持该联合方案在住院Covid-19成人中的安全性。
  • 原文未提供巴瑞替尼具体剂量、给药途径和频次,临床使用需参照药品说明书或当地指南。
  • 原文未明确排除人群,适用时需结合患者具体情况。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT04401579,资助方美国国家过敏和传染病研究所。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.

METHODS: We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15.

RESULTS: A total of 1033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P = 0.03), and a 30% higher odds of improvement in clinical status at day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21.0%; difference, -5.0 percentage points; 95% CI, -9.8 to -0.3; P = 0.03), as were new infections (5.9% vs. 11.2%; difference, -5.3 percentage points; 95% CI, -8.7 to -1.9; P = 0.003).

CONCLUSIONS: Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT04401579.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2020. PMID: 33306283. doi:10.1056/NEJMoa2031994

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。